Forbes -
6 Oct 2021 15:30

Moderna stock (NASDAQ: MRNA) declined by about 20% over the last week (five trading days) considerably underperforming the broader S&P 500 which was down by about 3% over the same period. There are a couple of recent developments that have hurt Moderna and Covid-19 vaccine stocks in general...
Share this Article